Here's the hottest stuff from UCB Pharma $UCB (+0,07%)
(Euronext: UCB / OTC: UCBJY) H1 2026 earnings, just released by the Belgian biopharma giant:
🚀 Blockbuster Power & Psoriasis Booster
UCB is really stepping up its game in the first half of 2026 thanks to its strong growth pipeline in the immunology and neurology sectors. The absolute superstar in the portfolio remains the anti-inflammatory drug Bimzelx® (bimekizumab):
Top-line momentum: Consolidated revenue continues to grow at a double-digit rate, setting a new record, thanks to strong demand for the core drivers.
Bimzelx® as a mega-growth engine: The IL-17A/IL-17F inhibitor is posting strong growth driven by the wave of global rollouts (including for plaque psoriasis and psoriatic arthritis) as well as the expanded approval for hidradenitis suppurativa (HS) .
Broad-based growth drivers: In addition to Bimzelx®, Fintepla® (epilepsy), Rystiggo® / Zilbrysq® (myasthenia gravis), and Evenity® (osteoporosis) are seeing strong volume growth.
🔮 Margin on track to meet the “Decade of Growth” target
Following the high market launch costs of recent years, UCB is now seeing a noticeable impact from its operational leverage:
Profitability is picking up: The Adjusted EBITDA is growing at a disproportionately higher rate relative to revenue, as marketing costs for the new products are declining in proportion to the rapidly rising volume.
Margin trajectory: UCB is rapidly approaching its medium-term target of an adjusted EBITDA margin of ≥30% , driven by the profitable blockbuster profile of Bimzelx®.
🤖 Confirmation of Ambitions & Outlook
2026 Full-Year Forecast on Track: Management reaffirms the outlook for full-year 2026 with high single-digit to low double-digit revenue growth (currency-adjusted).
Pipeline catalysts: With ongoing Phase 3 studies (including expansion of indications for pediatric patients and rare diseases), UCB is consistently building on the peak revenue potential for Bimzelx® (> 4 billion EUR) and Fintepla® (> 800 million EUR).
⚡ 💡 Jack’s Conclusion
UCB impressively demonstrates how a successful patent turnaround looks like! The transformation from a former pure CNS/epilepsy specialist (Vimpat/Briviact era) into a global immunology heavyweight is in full swing thanks to the unprecedented momentum of Bimzelx®.
The Quality Verdict: A flawless biopharma company with a well-stocked pipeline and excellent competitive moats thanks to patent-protected antibodies. If you want to bet on European biotech/pharma champions, there’s hardly any way around UCB right now! 💉💊